Objective: To describe maternal and neonatal morbidity and mortality among women with HIV infection and their infants. (OR 6.7,. Infants born by cesarean had increased odds of a low 5-minute Apgar score (OR 8.1,) and admission to an intensive care unit (OR 5.4,.
| INTRODUCTION
Approximately 18 million women are living with HIV type 1 infection worldwide. 1 Globally, HIV infection and maternal mortality remain the two leading causes of death for women aged 15-49 years. 2 Pregnant women with HIV infection have an estimated maternal mortality almost eight times higher than that of uninfected women, 3 and in areas with high prevalence, HIV infection is estimated to account for 12%-50% of maternal deaths. 4 Pregnancy-related morbidity is also increased in women with HIV infection: their risk of major puerperal sepsis is two times higher than that of uninfected women, and their risk of preterm labor and delivery is increased by 30%, even after adjusting for comorbidities, socioeconomic factors, and treatment with antiretroviral (ARV) therapy. 5 Increased risks of postpartum and neonatal morbidity have also been suggested with both elective and emergency cesarean delivery compared with vaginal delivery. 6, 7 Most of this evidence derives from resource-rich settings, and maternal morbidity and mortality among women with HIV infection in resource-limited settings was recently identified as a priority for researchers and stakeholders to assess and develop appropriate public health interventions. 8 To better describe maternal and neonatal outcomes among women
with HIV infection and their infants in a resource-limited setting, a secondary analysis was undertaken of the Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study, a clinical trial among 2369 mother-infant pairs. 9 The aims of the present secondary analysis were to describe serious maternal and neonatal morbidity and mortality among women with HIV infection and their infants, overall and by delivery type, and to determine risk factors for postpartum maternal complications or mortality.
| MATERIALS AND METHODS

Full details of the BAN Study-a randomized clinical trial of postnatal
ARVs for prevention of HIV transmission during breastfeeding-have been reported previously. an alanine aminotransferase concentration of no more than 2.5 times the upper limit of the normal range, no presence of other active serious infection, and no previous use of any ARV agents. Women who met these criteria were enrolled and followed up prospectively for up to four prenatal study visits, at which they received iron and folate supplements, screening for anemia and syphilis, malaria prophylaxis, mosquito nets, and tetanus toxoid vaccination. For the present analysis, serious maternal morbidity and mortality were examined at delivery (n=2791), from delivery to 6 weeks F I G U R E 1 Enrollment of mother-infant pairs. later (n=2369), and from 7 to 48 weeks (n=1980). Neonatal morbidity was examined for all singletons and first-born infants in multiple deliveries who had an initial infant evaluation form completed (n=2685). In addition to that infant form, maternal and neonatal morbidity outcomes were derived from delivery history questionnaires and records of laboratory adverse events and serious adverse events. Adverse events were graded using normative value cutoffs from toxicity tables for adults or infants from the National Institute of Health, Division of AIDS. 11 Serious adverse events were defined as any fatal or life-threatening event requiring hospitalization or prolongation of hospital stay, or which resulted in persistent or significant disability. Maternal mortality was defined as any death that occurred from delivery to 48 weeks. Neonatal death was defined as death by 28 days of life, and was assessed among singletons and first-born infants.
Maternal morbidity is defined as any health condition attributed to and/or aggravated by pregnancy and childbirth that has a negative impact on the woman's well-being. 12 For the present analysis, maternal morbidities were presented separately for delivery (pre-eclampsia/ eclampsia, hemorrhage, blood transfusion, intrapartum fever, puerperal sepsis/endometritis, stillbirth, and prolonged hospital stay) and postpartum (infection, grade 1-4 anemia) complications. Delivery complications were analyzed for all mothers who delivered during the study (n=2791). A "prolonged hospital stay" was defined as admission to the postpartum ward for more than 48 hours after vaginal delivery and more than 7 days after cesarean delivery. Stillbirth was defined as fetal loss at 20 weeks' gestation or more. The category "obstetric complications" included pre-eclampsia/eclampsia documented at delivery, maternal hemorrhage, blood transfusion, stillbirth, prolonged hospitalization stay, and infection up to 14 days after delivery. Postpartum complications were only assessed for women who underwent randomization (n=2369). "Infection" includes all instances of puerperal sepsis/endometritis, serious febrile illness/sepsis, malaria, intrapartum fever, pneumonia, meningitis, tuberculosis, pelvic inflammatory disease, and syphilis at delivery or from delivery to 2 weeks if a serious adverse event. Neonatal morbidity was defined as a low Apgar score, admission to the intensive care unit, low birth weight, macrosomia, or neonatal sepsis.
The data were stratified by mode of delivery: vaginal delivery, which includes natural spontaneous vaginal deliveries and vacuum deliveries; and cesarean delivery, which includes elective and emergency cesareans. Maternal and infant baseline characteristics were compared by mode of delivery using the Wilcoxon rank-sum test for continuous variables and χ 2 test for categorical variables. Potential predictors for maternal outcomes were evaluated with a manual backwards logistic regression (P<0.1 to stay); associations with neonatal outcomes have been reported previously. 13 The outcomes assessed were prolonged hospital stay, infection up to 14 days after delivery, anemia up to 6 weeks after delivery, and mortality up to 48 weeks after delivery. Potential predictors included mode of delivery, maternal age (>29 years), body mass index (<20, calculated as weight in kilograms divided by the square of height in meters), CD4+
T-cell count (<500 cells per μL), log HIV viral load, prenatal anemia (hemoglobin <110 g/L), and hemorrhage. All analyses were adjusted for the maternal ARV and nutritional study group. Data were analyzed using SAS 9.3 (SAS Institute, Cary, NC, USA). P<0.05 was considered significant. as pre-eclampsia/eclampsia at delivery, stillbirth, prolonged hospitalization, and infection by 2 weeks were also increased with cesarean (Table 2) . There were no maternal deaths in the first 42 days after delivery, but 9 (0.5%) of the 1980 women followed up through 48 weeks died:
| RESULTS
three due to complications of tuberculosis, two due to renal failure, and one each due to hepatic necrosis, pneumonia, perforated viscus, and unknown cause. Cesarean delivery was not associated with maternal mortality (Table 2 ), but women with postpartum anemia (≤48 weeks;
hemoglobin <110 g/L) had four-times higher odds of mortality than did mothers without anemia (aOR 4.8, 95% CI 1.2-19.4).
Stillbirth was recorded for 45 (1.7%) of 2649 infants. Low birth weight (>2000 g and ≤2500 g) was recorded for 283 (10.6%) of 2670 neonates, and 239 (8.9%) of 2679 were admitted to an intensive care unit. Cesarean delivery was associated with increased odds of low Apgar scores at 5 minutes and admission to an intensive care unit compared with vaginal delivery (Table 3 ).
There were 12 (0.4%) neonatal deaths, which occurred in the first 22 days of life: six from neonatal sepsis, three from pneumonia, one from sudden infant death of unknown etiology, one from complications of diabetes insipidus, and one from an acute illness of unknown etiology. There was no significant association between mode of delivery and neonatal death ( Table 3 ). The neonatal mortality rate 
| DISCUSSION
In the present study, 9% of mothers had one or more complication within 2 weeks of delivery, with the odds of any complication significantly increased with cesarean delivery. Cesarean delivery was also associated with blood loss and increased odds of preeclampsia/eclampsia at delivery, stillbirth, prolonged hospital stay, infection within the first 14 days, and anemia within 6 weeks of delivery. Neonates born by cesarean also had higher odds of The proportion of missing data differed significantly by delivery method for HIV viral load and body mass index, with a lower proportion of women who delivered vaginally than delivering by cesarean missing these data. l Data missing for 7 (6 vaginal delivery, 1 cesarean delivery). m Calculated as weight in kilograms divided by the square of height in meters. Data missing for 665 (612 vaginal delivery, 53 cesarean delivery). n Data missing for 55 (50 vaginal delivery, 5 cesarean delivery).
complications than did those delivered vaginally, including a low 5-minute Apgar score and admission to an intensive care unit.
These results highlight potential areas for improved outcomes and CD practices.
Cesareans have previously been associated with increased postpartum morbidity among women with and without HIV infection in resource-rich and resource-limited settings. 6, 7, 14 The risk of complications is highest for emergency cesarean delivery, and intermediate for elective cesarean. 6 In Malawi, cesarean delivery is rare (4.6%) and mostly performed as an emergency without preoperative preparation, 15 so it is not surprising that 91% of cesareans in the BAN Study were emergency procedures and had a higher complication rate than vaginal deliveries.
More than one-third of BAN mothers were anemic within 6 weeks of delivery, and the strongest predictors for postpartum anemia were prenatal anemia, cesarean delivery, and obstetric hemorrhage. Prenatal and postpartum anemia were associated with maternal infection within 2 weeks of delivery and maternal mortality by 48 weeks, respectively. In a matched-pairs analysis of Swiss women with and without HIV infection undergoing elective cesarean delivery, 16 postoperative anemia occurred in 49% of women with HIV infection and 9% of uninfected women. In the European
Collaborative Study, 17 mild anemia was the most prevalent complication among women with and without HIV infection after cesarean delivery, but it was more frequent among women with HIV infection.
In Malawi, the prevalences of anemia and severe anemia (grade 3-4) during pregnancy range from 39% to 72% and 3.6% to 4.0%, respectively. 18 The estimated relative risks of mortality associated with moderate and severe anemia for women in low-income countries have been reported as 1.35 and 3.51, respectively. 18 The women in the BAN Study received iron and folate supplements and underwent screening for anemia, which could explain the lower anemia prevalence in this HIV cohort compared with the other estimates from
Malawi. These data suggest that prenatal surveillance and improved T A B L E 2 Labor characteristics and maternal morbidity and mortality, by delivery type. Maternal and neonatal deaths were rare. Worldwide, 75% of maternal deaths are due to hemorrhage, infection, severe preeclampsia/eclampsia, complications of delivery, and unsafe abortion; the remaining deaths are due to indirect causes such as malaria, HIV/AIDS, anemia, and tuberculosis. 21 In Malawi, hemorrhage, infection, and hypertensive disorders of pregnancy are the three leading causes of maternal death; 22 the maternal mortality ratio is estimated as 680 deaths per 100 000 live births. 23 In the present study, maternal mortality was zero during the immedi- 
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